The invention refers to the treatment and prevention of diseases with paf antagonists mediated by the precursor and metabolite lyso paf and a procedure for determining their efficacy.
The binding of chemotactic factors such as paf-acether (paf, Benveniste et al., J. Exp. Med. 1972, 136: 1356)) to